Are you a recent PhD graduate with a passion for Data Science and Artificial Intelligence? Are you ready to apply and expand your skills to advance drug discovery and development for patients? Our Novartis Data Science Innovation Fellowship Program offers a unique opportunity to join a diverse and vibrant community of data researchers through a dedicated pharma training program for early-career scientists. We are accepting applications for 2-3 year fellowships at our Basel (CH) and Cambridge, MA (US) Biomedical Research sites through July 29. Imagine the career you could have at Novartis, and apply now: https://lnkd.in/gK-wiw6Y #datascience #datasciencecareers
About us
We’re driven by the Novartis purpose: To deliver innovative medicines that alleviate society’s greatest disease burdens. As a focused R&D engine, we’re designed to turn breakthrough science into transformative, high-value treatments that have the most potential to improve and extend the lives of patients. See our community guidelines: https://go.novartis.social/3Slt0Up
- Website
-
https://www.novartis.com/research-development
External link for Novartis Science
- Industry
- Pharmaceutical Manufacturing
- Company size
- 5,001-10,000 employees
- Headquarters
- Cambridge, MA
Updates
-
In Science, our researchers identify a protein involved in the suppression of fetal hemoglobin, and report the discovery of small molecules that could potentially be used to degrade this novel target to treat sickle cell disease. https://lnkd.in/gh8Ft3g2 #hematology #sicklecelldisease #TPD
-
Novartis researchers have developed a new stretch device and 192-well cell stretch plate that enables high-throughput study of gene expression as cells respond to mechanical stress – an important factor in understanding cell biology and identifying potential targets for drug discovery. Read their paper in APL Bioengineering: https://lnkd.in/gvpFxM_8 #mechanobiology #drugdiscovery
A new cell stretch device for mechanobiology research in drug discovery
pubs.aip.org
-
Each year we welcome summer interns to our labs to apply their research skills and to learn about drug discovery and development. Many of these interns come to our Cambridge research site through the Summer of Science program, now in its 19th year. This year’s cohort includes 29 undergraduates from 25 different universities and research institutes. We wish a warm welcome and much success to all of our interns! Learn more about our internship programs here: https://lnkd.in/gKRRft6c #STEMinternships
-
-
Do you have a life sciences background? Are you curious about the world of drug discovery, or looking for a career with the potential to impact patients’ lives? Novartis, in collaboration with Davidson College and Coursera, is offering a six-course program on preclinical drug discovery. Learn more about the science and considerations behind the search for novel medicines in this self-paced online program: https://lnkd.in/gJHKUEQ2 Full description here: Drug Hunting: The Science of Making Medicines Preclinical drug discovery is a complex, challenging, and iterative hunt for novel new medicines to address the unmet medical needs of patients. The science and considerations behind this endeavour are covered in this online six course program, which begins with an Introduction to Drug Hunting, followed by in-depth discussions of Targets, Assays and Screening, Lead Selection and Optimization, Pharmacokinetics, Preclinical Safety, and Preformulation. Each course is self-paced, comprised of short 5-minute videos covering selected topics, accompanied by additional readings and problems designed to reinforce and deepen understanding of those topics. This program is intended for a graduate level audience with a life sciences background. #careerdevelopment #drugdiscovery #lifesciencecareers
Drug Hunting: The Science of Making New Medicines
coursera.org
-
Novartis announced an agreement to acquire Mariana Oncology, a preclinical-stage biotechnology company focused on developing novel radioligand therapies (RLTs) to treat cancers where there is high unmet patient need. https://lnkd.in/gqaSAgAT
-
Novartis, PeptiDream have entered into an agreement to expand their discovery collaboration aimed at identifying novel peptides for potential use in radioligand therapy and other contexts https://lnkd.in/dYweVREt
-
Yesterday, Novartis and Medicines for Malaria Venture announced results from the CALINA study. The Phase 2/3 trial showed positive efficacy and safety data for a potential medicine formulated for the smallest babies with malaria, for whom there is currently no evidence-based treatment. https://lnkd.in/ecV8BHmv #malaria #WorldMalariaDay
-
-
Meet Dr. Mamadou Tekete of the Malaria Research and Training Center, University of Sciences (Bamako, Mali). He’s one of the researchers with Project Africa GRADIENT, a collaboration between Novartis, GSK and the South African Medical Research Council that supports researchers across Africa who are studying the potential impact of genetic diversity on individuals’ response to medicines. Here, Dr. Tekete explains his work on genetic diversity and pharmacokinetics in malaria, and its potential relevance to personalized medicine. #pharmacokinetics #personalizedmedicine #geneticdiversity
-
Dr. Houcemeddine Othman, a researcher at the Sidner Brenner Institute for Molecular Bioscience in South Africa, and his team are developing a comprehensive map of genetic variations that may impact the metabolization of drugs for malaria and tuberculosis. Learn how Project Africa GRADIENT, a collaboration between Novartis, GSK & the South African Medical Research Council, is supporting his work and helping to build a network of researchers in this field across Africa. #genetics #malaria #diseaseresearch